Icotrokinra, the new kid on the bloc! Targeted oral peptide IL-23R-inhibitor Effective in Ph2 and Ph3 in PSO Adults Data in Adolescents (12-18yo) with PSO ICO 200mg QD 44pts vs. PBO 22pts 16wks All pts received ICO wk16-wk24 Clear/Almost clear skin IGA 0/1 84% vs. 24% PASI 90 https://t.co/77YvXtdLi1

• https://x.com/AurelieRheumo/status/1982834233430196411/photo/1
• https://x.com/AurelieRheumo/status/1982834233430196411/photo/1
• https://x.com/AurelieRheumo/status/1982834233430196411/photo/1

POETYK-PsA 1 & 2 Phase 3 RCT TYK2i Deucravacitinib Pooled analysis 640+pts PBO vs. 640+pts DEUCRA 6mg QD MDA 12% vs 22% All elements of MDA response sig different except for Leeds enthesitis index DAPSA Remission 2% vs. 9% PsARC 42% vs. 61% PASDAS -1 vs. -1.7 mCPDAI -1.2 vs. -1.9 https://t.co/OTOFxTOrRp

• https://x.com/AurelieRheumo/status/1982831486026826168/photo/1
• https://x.com/AurelieRheumo/status/1982831486026826168/photo/1

#ACR25 Abstr#1535 This is super-cool & watch this space! Novel Bi-specific T-cell Engager using pan-gamma delta TCR instead of currently used CD3. In vitro study = complete B-cell depletion comparable to other BiTE, but with a more favorable cytokine release profile @RheumNow https://t.co/PtR5g3gCPH

• https://x.com/Yuz6Yusof/status/1982829570597535882/photo/1
• https://x.com/Yuz6Yusof/status/1982829570597535882/photo/1

Abstract 0874: At wk16, deucravacitinib (vs placebo) showed greater efficacy in multiple #PsA disease activity measures 🔹 ↑ MDA, DAPSA LDA/remission, and PsARC responses 🔹 Greater ↓in PASDAS and mCPDAI 🔹 Benefits seen in both men and women @RheumNow #ACR25

REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR). https://t.co/CLmCdBXiOf https://t.co/z20nWd2NSM

• REPLENISH - Secukinumab Works in Polymyalgia Rheumatica | RheumNow

Next Generation T-Cell Engager: The Future https://t.co/gcrfzV6MSJ via @YouTube @alhkim great to see you and hearing all about new T cell Engager , feasibility and less toxicity. @RheumNow #ACR25

• Next Generation T-Cell Engager: The Future

Summary of (some) drugs in the pipeline for management of PAH. Slide credits: Dr Benjamin Freed ⁦@RheumNow⁩ #ACR2025 https://t.co/qazQNk4ovR

• https://x.com/MartinezZayasMd/status/1982817190987354258/photo/1

#ACR25 Abstr#1525 Find me at poster hall. Super-responders exist with rituximab, not just confined to CAR-T! Our cohort study = 23/114 (20%) had resp duration >3-yrs; 15/23 were IS-Free. Poor prognostics (Non-White, APS) & shorter #SLE duration predicted super-tesponse @RheumNow https://t.co/nJQFmiIj2n

• https://x.com/Yuz6Yusof/status/1982822156774846648/photo/1
• https://x.com/Yuz6Yusof/status/1982822156774846648/photo/1

#ACR25 Abstr#663 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 8 #SLE patients in Phase 1. Advantages over autologous/allogenic: -No apheresis -No conditioning chemo -Shorter hospital stays ~3 days -Ability to redose in partial responder @RheumNow https://t.co/pbem7A5Iq5

• https://x.com/Yuz6Yusof/status/1982589256527753433/photo/1
• https://x.com/Yuz6Yusof/status/1982589256527753433/photo/1

💊 SGLT2i vs GLP-1 in Lupus Nephritis TriNetX evaluating the impact of GLP-1 agonists vs SGLT-2 inhibitors on outcomes of lupus nephritis 📊 GLP-1 use linked to better renal & CV outcomes in LN including: ⬇️ CKD progression ⬇️ Mortality ⬇️ Acute MI @RheumNow #ACR25 https://t.co/v4LgKFDt68

• https://x.com/AkhilSoodMD/status/1982548790080049436/photo/1